GlassScriptPhysician profile
Basharath M Khan
NPI 1205153053
$5,031.11
in general payments reported to CMS, 2019-2025
50 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $393 · 2021: $748 · 2022: $405 · 2023: $954 · 2024: $1,118 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.16 |
| Education | $144.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $668.86 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $658.57 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $254.78 | 2022-2025 | Pomalyst, Reblozyl |
| Seagen INC. | $248.24 | 2020-2025 | Adcetris, Tukysa |
| Abbvie INC. | $226.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $217.54 | 2021-2025 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $207.33 | 2020-2025 | Imfinzi, Enhertu |
| Pfizer INC. | $194.25 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.85 | 2019-2025 | Fruzaqla, Iclusig |
| Amgen INC. | $158.58 | 2020-2022 | |
| Janssen Biotech, INC. | $125.09 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Exelixis INC. | $122.15 | 2019-2025 | Cabometyx |
| Octapharma USA, INC. | $121.63 | 2025 | Octagam Immune Globulin (Human) |
| Daiichi Sankyo INC. | $101.92 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Gilead Sciences, INC. | $97.98 | 2021-2025 | Trodelvy |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basharath Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.